This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Evaluate historical worst drawdowns for index funds and translate insights into practical risk controls and withdrawal planning.
14,434 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Bitwise CIO Matt Hougan argues that Strategy's STRC selloff reflects end-of-cycle deleveraging preceding a bitcoin bo...
Tech investors brace for the second half of 2026 as hyperscaler capex guidance from major cloud players could reshape...
Global regulators are tightening the rules around AI financing as investment soars, signaling potential shifts in fun...
As SpaceX gears up for a potential IPO, spacex’s lead underwriters have produced a dramatic split in value views, cre...
Two veteran venture partners unveil a method to identify future unicorn founders with momentum, using a four-domain, ...
The AI IPO wave is heating up, and Anthropic sits at the center. This guide explains how early backers could see wind...
A well-known trading app moving deeper into crypto and tokenized assets could reshape where traders park capital. Thi...
SpaceX's public debut sparked wide debate. This guide explains what a $2,000 investment could look like under differe...
Bitcoin holds a narrow path near the $64,000 level as Michael Saylor drops another orange dot hint, reigniting debate...
Bahrain’s EDB chief Noor outlines a growth-focused strategy to lure capital despite regional headwinds. bahrain edb’s...
A high-stakes pivot: the team behind ethereum's institutional privacy push launches EthSystems, a for-profit venture ...